---
layout: default
title: Terbutaline
description: "Terbutaline çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 165
evidence_level: L5
indication_count: 3
---

# Terbutaline

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Terbutaline è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Terbutaline å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Terbutalineï¼ˆç‰¹å¿…æ—ï¼‰æ˜¯é¸æ“‡æ€§ beta-2 è…ä¸Šè…ºç´ å—é«”ä¿ƒæ•ˆåŠ‘ï¼ŒTxGNN é æ¸¬å…¶å°é˜»å¡æ€§è‚ºç—…å…·ç™‚æ•ˆï¼Œå·²æœ‰å¤§é‡è‡¨åºŠè©¦é©—è­‰æ“šæ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Terbutaline |
| DrugBank ID | DB00871 |
| å°ç£å•†å“å | å–˜å…‹æ³¨å°„æ¶²ã€ç‰¹å¿…æ—éŒ ã€å¸ƒä¹ƒå¯éŒ ç­‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | æ”¯æ°£ç®¡æ€§æ°£å–˜ã€æ”¯æ°£ç®¡ç‚ã€è‚ºæ°£è…« |
| é æ¸¬æ–°é©æ‡‰ç—‡ | bronchitisã€dry eye syndromeã€obstructive lung disease |
| æœ€é«˜è­‰æ“šç­‰ç´š | **L1**ï¼ˆå¤šå€‹ RCTï¼‰ |
| TxGNN åˆ†æ•¸ | 0.892ï¼ˆé˜»å¡æ€§è‚ºç—…ï¼‰ |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

### ä½œç”¨æ©Ÿè½‰æ”¯æŒ

Terbutaline é¸æ“‡æ€§ä½œç”¨æ–¼ beta-2 è…ä¸Šè…ºç´ å—é«”ï¼Œé€ æˆæ”¯æ°£ç®¡å¹³æ»‘è‚Œé¬†å¼›ï¼Œæ“´å¼µæ°£é“ã€‚æ­¤æ©Ÿè½‰å°æ‰€æœ‰é˜»å¡æ€§å‘¼å¸é“ç–¾ç—…ï¼ˆåŒ…æ‹¬æ°£å–˜ã€COPDã€æ…¢æ€§æ”¯æ°£ç®¡ç‚ï¼‰å‡æœ‰æ•ˆã€‚

### é æ¸¬é©æ‡‰ç—‡åˆ†æ

**é˜»å¡æ€§è‚ºç—…ï¼ˆCOPDï¼‰**
- TxGNN åˆ†æ•¸ï¼š0.892ï¼ˆæ’åç¬¬ 1ï¼‰
- æ©Ÿè½‰é«˜åº¦ç›¸é—œï¼šæ”¯æ°£ç®¡æ“´å¼µä½œç”¨ç›´æ¥æ”¹å–„æ°£æµé˜»å¡
- èˆ‡ç¾æœ‰é©æ‡‰ç—‡ï¼ˆæ°£å–˜ã€æ”¯æ°£ç®¡ç‚ã€è‚ºæ°£è…«ï¼‰é«˜åº¦é‡ç–Š
- COPD æœ¬è³ªä¸ŠåŒ…å«æ…¢æ€§æ”¯æ°£ç®¡ç‚å’Œè‚ºæ°£è…«ï¼Œå› æ­¤é æ¸¬æ¥µç‚ºåˆç†

## è‡¨åºŠè©¦é©—è­‰æ“š

### COPD/é˜»å¡æ€§è‚ºç—…ç›¸é—œè©¦é©—ï¼ˆè¶…é 50 é …ï¼‰

| NCT ç·¨è™Ÿ | è©¦é©—åç¨± | éšæ®µ | ç‹€æ…‹ |
|----------|----------|------|------|
| NCT00239577 | æ”¯æ°£ç®¡æ“´å¼µåŠ‘å° COPD æ‚£è€…å‘¼å¸å›°é›£ä¹‹å½±éŸ¿ | Phase 4 | å·²å®Œæˆ |
| NCT00216437 | Terbutaline vs Tiotropium åœ¨ COPD æ‚£è€…çš„æ¯”è¼ƒ | Phase 4 | å·²å®Œæˆ |
| NCT01072396 | COPD æ‚£è€…æ”¯æ°£ç®¡æ“´å¼µåŠ‘åæ‡‰æ€§ç ”ç©¶ | Phase 4 | å·²å®Œæˆ |
| NCT00158821 | é é˜²é‹å‹•èª˜ç™¼æ”¯æ°£ç®¡ç—™æ”£ç ”ç©¶ | Phase 4 | å·²å®Œæˆ |
| NCT00527072 | Formoterol vs Terbutaline åœ¨ COPD æ‚£è€…çš„é•·æœŸæ¯”è¼ƒ | Phase 4 | å·²å®Œæˆ |
| NCT02275234 | COPD æ‚£è€…ä½é™¢æœŸé–“æ”¯æ°£ç®¡æ“´å¼µåŠ‘çµ¦äºˆæ–¹å¼æ¯”è¼ƒ | Phase 4 | å·²å®Œæˆ |
| NCT01587924 | å¸å…¥å‹æ”¯æ°£ç®¡æ“´å¼µåŠ‘å° COPD æ‚£è€…è†ˆè‚ŒåŠŸèƒ½å½±éŸ¿ | Phase 4 | å·²å®Œæˆ |

### è©¦é©—æ‘˜è¦

å¤§é‡è‡¨åºŠè©¦é©—ç¢ºèª Terbutaline åœ¨ COPD æ²»ç™‚ä¸­çš„è§’è‰²ï¼š
- æ”¹å–„ FEV1 å’Œå‘¼å¸å›°é›£ç—‡ç‹€
- èˆ‡å…¶ä»–æ”¯æ°£ç®¡æ“´å¼µåŠ‘ï¼ˆTiotropiumã€Formoterolï¼‰ç™‚æ•ˆç›¸ç•¶
- å¯ç”¨æ–¼æ€¥æ€§ç™¼ä½œå’Œç¶­æŒæ²»ç™‚
- å™´éœ§å™¨å’Œå¸å…¥å™¨çµ¦è—¥å‡æœ‰æ•ˆ

## æ–‡ç»è­‰æ“š

### COPD ç›¸é—œæ–‡ç»

ç”±æ–¼ Terbutaline ç”¨æ–¼ COPD å·²æ˜¯æˆç†Ÿçš„è‡¨åºŠå¯¦è¸ï¼ŒPubMed æ–‡ç»æ¥µç‚ºè±å¯Œï¼Œä¸»è¦é¡å‹åŒ…æ‹¬ï¼š

1. **è—¥æ•ˆå­¸ç ”ç©¶**ï¼šç¢ºèªæ”¯æ°£ç®¡æ“´å¼µæ•ˆæœ
2. **æ¯”è¼ƒç ”ç©¶**ï¼šèˆ‡å…¶ä»– beta-2 ä¿ƒæ•ˆåŠ‘å’ŒæŠ—è†½é¹¼è—¥ç‰©æ¯”è¼ƒ
3. **å®‰å…¨æ€§ç ”ç©¶**ï¼šé•·æœŸä½¿ç”¨çš„å¿ƒè¡€ç®¡å®‰å…¨æ€§
4. **çµ¦è—¥æ–¹å¼ç ”ç©¶**ï¼šå™´éœ§å™¨ vs å¸å…¥å™¨çš„æ•ˆæœæ¯”è¼ƒ

### è­‰æ“šå¼·åº¦è©•ä¼°

- è‡¨åºŠè©¦é©—ï¼šè¶…é 50 é …ï¼Œå¤šç‚º Phase 4
- æ–‡ç»è­‰æ“šï¼šæ¥µç‚ºè±å¯Œ
- **ç¶œåˆè­‰æ“šç­‰ç´šï¼šL1**ï¼ˆå¤šå€‹ RCT ç¢ºèªç™‚æ•ˆï¼‰

## å°ç£ä¸Šå¸‚è³‡è¨Š

### å·²æ ¸å‡†ç”¢å“

| è¨±å¯è­‰è™Ÿ | å•†å“å | åŠ‘å‹ | å«é‡ |
|----------|--------|------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬041766è™Ÿ | å–˜å…‹æ³¨å°„æ¶² 0.2mg/mL | æ³¨å°„åŠ‘ | 0.2mg/mL |
| è¡›ç½²è—¥è£½å­—ç¬¬026805è™Ÿ | ç‰¹å¿…æ—éŒ  2.5mg | éŒ åŠ‘ | 2.5mg |
| è¡›ç½²è—¥è£½å­—ç¬¬019714è™Ÿ | å¸ƒä¹ƒå¯éŒ  2.5mg | éŒ åŠ‘ | 2.5mg |
| è¡›ç½²è—¥è£½å­—ç¬¬033582è™Ÿ | ç‰¹å¿…æ—æ¶² | å£æœæ¶² | - |

### å¥ä¿çµ¦ä»˜ç‹€æ…‹

æ‰€æœ‰åŠ‘å‹å‡æœ‰å¥ä¿çµ¦ä»˜ï¼Œå±¬æ–¼åŸºæœ¬å‘¼å¸é“ç”¨è—¥ã€‚

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|--------------|----------|------|
| Beta é˜»æ–·åŠ‘ | ä¸­åº¦ | æ‹®æŠ—ä½œç”¨ï¼Œé™ä½ç™‚æ•ˆ |
| MAO æŠ‘åˆ¶åŠ‘ | ä¸­åº¦ | å¯èƒ½å¢å¼·å¿ƒè¡€ç®¡å‰¯ä½œç”¨ |
| ä¸‰ç’°æŠ—æ†‚é¬±åŠ‘ | ä¸­åº¦ | å¯èƒ½å¢å¼·å¿ƒè¡€ç®¡å‰¯ä½œç”¨ |
| åˆ©å°¿åŠ‘ | è¼•åº¦ | å¯èƒ½åŠ é‡ä½è¡€é‰€ |

### ä¸»è¦ä¸è‰¯åæ‡‰

- **å¸¸è¦‹**ï¼šå¿ƒæ‚¸ã€æ‰‹æŠ–ã€é ­ç—›ã€è‚Œè‚‰ç—™æ”£
- **è¼ƒå°‘è¦‹**ï¼šå¿ƒå¾‹ä¸æ•´ã€ä½è¡€é‰€
- **ç½•è¦‹**ï¼šéæ•åæ‡‰

### ç‰¹æ®Šæ—ç¾¤æ³¨æ„äº‹é …

- **å¿ƒè¡€ç®¡ç–¾ç—…**ï¼šè¬¹æ…ä½¿ç”¨ï¼Œç›£æ¸¬å¿ƒç‡
- **ç³–å°¿ç—…**ï¼šå¯èƒ½å½±éŸ¿è¡€ç³–æ§åˆ¶
- **ç”²ç‹€è…ºäº¢é€²**ï¼šå¯èƒ½åŠ é‡ç—‡ç‹€
- **æ‡·å­•**ï¼šCategory Bï¼Œæ›¾ç”¨æ–¼å®‰èƒä½†æœ‰çˆ­è­°


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**å¿ƒè¡€ç®¡ç–¾ç—… (Cardiovascular Diseases)** ğŸŸ¡ Moderate
- Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; pr...

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¡ Moderate
- Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commerciall...

**Hypokalemia** ğŸŸ¡ Moderate
- Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically signific...

**Seizures** ğŸŸ¡ Moderate
- Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of thes...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬å¯ä¿¡åº¦è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | å¯ä¿¡åº¦ | å»ºè­° |
|------------|----------|--------|------|
| é˜»å¡æ€§è‚ºç—…ï¼ˆCOPDï¼‰ | L1 | æ¥µé«˜ | å·²æ˜¯æˆç†Ÿè‡¨åºŠå¯¦è¸ |

### è‡¨åºŠæ‡‰ç”¨å»ºè­°

1. **COPD æ€¥æ€§ç™¼ä½œ**ï¼šå¯ä½œç‚ºçŸ­æ•ˆæ”¯æ°£ç®¡æ“´å¼µåŠ‘ä½¿ç”¨
2. **COPD ç¶­æŒæ²»ç™‚**ï¼šé€šå¸¸å„ªå…ˆé¸ç”¨é•·æ•ˆè£½åŠ‘ï¼ˆLABAï¼‰ï¼ŒTerbutaline ä½œç‚ºå‚™ç”¨
3. **åˆä½µæ°£å–˜çš„ COPD**ï¼šTerbutaline ç‰¹åˆ¥é©åˆ

### å¯¦å‹™è€ƒé‡

Terbutaline ç”¨æ–¼ COPD é›–éã€Œæ–°é©æ‡‰ç—‡ã€ï¼Œä½† TxGNN çš„é æ¸¬è­‰å¯¦å…¶è‡¨åºŠåƒ¹å€¼ã€‚åœ¨å°ç£ï¼ŒTerbutaline ä¸»è¦é©æ‡‰ç—‡æ¨™ç¤ºç‚ºæ°£å–˜å’Œæ”¯æ°£ç®¡ç‚ï¼Œè‹¥èƒ½æ˜ç¢ºç´å…¥ COPD é©æ‡‰ç—‡ï¼Œå°‡ä½¿è™•æ–¹æ›´ç‚ºæ˜ç¢ºã€‚

### èˆ‡å…¶ä»–è—¥ç‰©çš„å®šä½æ¯”è¼ƒ

| è—¥ç‰©é¡åˆ¥ | ä»£è¡¨è—¥ç‰© | å„ªå‹¢ | åŠ£å‹¢ |
|----------|----------|------|------|
| SABAï¼ˆå« Terbutalineï¼‰ | Terbutaline, Salbutamol | å¿«é€Ÿèµ·æ•ˆã€æ€¥æ•‘ç”¨ | ä½œç”¨æ™‚é–“çŸ­ |
| LABA | Formoterol, Salmeterol | ä½œç”¨æ™‚é–“é•· | èµ·æ•ˆè¼ƒæ…¢ |
| LAMA | Tiotropium | 24 å°æ™‚ä½œç”¨ | èµ·æ•ˆè¼ƒæ…¢ |

---

*æœ¬ç­†è¨˜ç”± TxGNN é æ¸¬ç³»çµ±ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*æ›´æ–°æ—¥æœŸï¼š2026-02-11*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Voriconazole]({{ "/drugs/voriconazole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Levamisole]({{ "/drugs/levamisole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Trastuzumab Deruxtecan]({{ "/drugs/trastuzumab_deruxtecan/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pentosan Polysulfate]({{ "/drugs/pentosan_polysulfate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Vigabatrin]({{ "/drugs/vigabatrin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Terbutalineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/terbutaline/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_terbutaline,
  title = {Terbutalineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/terbutaline/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
